Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis

Beraza, N.; Malato, Y.; Borght, S. Vander; Liedtke, C.; Wasmuth, H. E.; Dreano, M.; De Vos, R.; Roskams, T.; Trautwein, C.
May 2008
Gut;May2008, Vol. 57 Issue 5, p655
Academic Journal
BACKGROUND: Non-alcoholic-steatohepatitis (NASH) leading to fibrosis, end-stage cirrhosis and hepatocellular carcinoma is an increasing health problem in the Western world. Thus, the need for new therapeutic approaches is increasing. IKK2 plays a key role in the development of NASH by mediating inflammation and insulin resistance. AIM: Here the beneficial effects of a pharmacological IKK2 inhibitor (AS602868) on initial stages of NASH progression were tested. METHODS: Mice were fed with a high sucrose diet (HSD) and daily-administered AS602868 and vehicle. The impact of AS602868 on NASH progression was studied using biochemical, histological and molecular markers. RESULTS: AS602868 treatment prevented HSD-induced weight gain and visceral fat accumulation. In adipose tissue, AS602868-treated mice exhibited a lower degree of infiltrated macrophages along with reduced proinflammatory cytokine production. Further analysis demonstrated that AS602868 treatment efficiently inhibited nuclear factor (NF)-κB activation in liver non-parenchymal cells and as a consequence attenuated the inflammatory response in the liver. Accordingly, in HSD/AS602868 mice, liver and adipose tissue adiponectin levels remained at levels comparable with those of control chow-fed mice, while they were decreased in HSD/vehicle animals. Additionally, AS602868 improved lipid β-oxidation mediated by peroxisome proliferator-activated receptor (PPAR) α and PPARγ. Systemic pharmacological IKK2 inhibition by AS602868 treatment efficiently prevented liver steatosis and inflammation, and improved antioxidant response. All this contributed to attenuation of NASH progression as evidenced by lower hepatocyte apoptosis and early stages of liver fibrosis. CONCLUSION: The data demonstrate that AS602868-mediated IKK2 inhibition represents a new therapeutic approach to prevent dietary-induced NASH progression.


Related Articles

  • Efficacy of Tiopronin in treatment of severe non-alcoholic fatty liver disease. M.-C. TANG; L. CHENG; L. QIU; R.-G. JIA; R.-Q. SUN; X.-P . WANG; G.-Y . HU; Y . ZHAO // European Review for Medical & Pharmacological Sciences;Jan2014, Vol. 18 Issue 2, p160 

    BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome of which the main feature is diffuse macrovesicular hepatic steatosis caused by deposition of excessive free fatty acid and triglyceride in liver parenchyma. AIM: To observe the efficacy of Tiopronin in...

  • Liver Fibrosis Culprit. Breindl, Anette // BioWorld Today;8/19/2013, Vol. 24 Issue 158, p1 

    The article discusses research done by researchers from the German University of Erlangen-Nuremberg which identified an interleukin that plays an important role in liver fibrosis, published in the August 15, 2013 issue of "Immunity."

  • Je jaterní fibróza reverzibilní proces? Lenka, Bittnerová // Occupational Medicine / Pracovní Lékarství;2013, Vol. 65 Issue 1/2, p48 

    Liver fibrosis if the consequence of most diverse causes or stimuli - it is the consequence chronic liver diseases such as virus hepatitis or autoimmune hepatitis, alcohol abuse, effects of toxins or biliary damage. In occupational pathology we rarely encounter the action of hepatotoxic...

  • The Dutch Vision of Clinical Pharmacology. Schellens, J. H. M.; Grouls, R.; Guchelaar, H. J.; Touw, D. J.; Rongen, G. A.; de Boer, A.; Van Bortel, L. M. // Clinical Pharmacology & Therapeutics;Apr2009, Vol. 85 Issue 4, p366 

    Recent position papers addressing the profession of clinical pharmacology have expressed concerns about the decline of interest in the field among clinicians and medical educators in the United Kingdom and other Western countries, whether clinical pharmacology is actually therapeutics, and...

  • Clinical Pharmacology Education: Looking into the Future. Gray, J. D.; Danoff, D.; Shepherd, A. M. // Clinical Pharmacology & Therapeutics;Feb2007, Vol. 81 Issue 2, p305 

    The numbers of specialists who are practicing Clinical Pharmacology is declining. This raises questions about the nature of the discipline and the roles of those who practice Clinical Pharmacology. Numbers and qualifications of successful trainees in North American accredited Clinical...

  • Congenital Hepatic Fibrosis. Tewarson, Ivan P.; Crowe, Peter; Verhagen, Arie D. // Clinical Pediatrics;Nov1964, Vol. 3 Issue 11, p679 

    Discusses the pathogenesis of congenital hepatic fibrosis. Cause of congenital hepatic fibrosis; Manifestations of the disease; Citation of case report about a ten-year-old white male with congenital hepatic fibrosis; Clinical diagnosis.

  • The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. Nobili, Valerio; Alisi, Anna; Vania, Andrea; Tiribelli, Claudio; Pietrobattista, Andrea; Bedogni, Giorgio // BMC Medicine;2009, Vol. 7, Special section p1 

    Background: Liver fibrosis is a stage of non-alcoholic fatty liver disease (NAFLD) which is responsible for liver-related morbidity and mortality in adults. Accordingly, the search for noninvasive markers of liver fibrosis has been the subject of intensive efforts in adults with NAFLD. Here, we...

  • Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Braet, Filip; Wisse, Eddie // Comparative Hepatology;2002, Vol. 1, p1 

    This review provides a detailed overview of the current state of knowledge about the ultrastructure and dynamics of liver sinusoidal endothelial fenestrae. Various aspects of liver sinusoidal endothelial fenestrae regarding their structure, origin, species specificity, dynamics and formation...

  • Genetic determinants of alcoholic liver disease. Stickel, Felix; Hampe, Jochen // Gut;Jan2012, Vol. 61 Issue 1, p150 

    Alcoholic liver disease (ALD) accounts for the majority of chronic liver disease in Western countries. The spectrum of ALD includes steatosis with or without fibrosis in virtually all individuals with an alcohol consumption of >80 g/day, alcoholic steatohepatitis of variable severity in 10-35%...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics